SCHEDULE 13D/A: Sarissa Capital Significantly Reduces Innoviva Stake, Exiting Major Shareholder Status

Sarissa Capital Management LP and Alexander J. Denner have significantly reduced their beneficial ownership in Innoviva, Inc. to below 5%, ceasing to be subject to certain SEC reporting requirements.

Summary

• Sarissa Capital Management LP and Alexander J. Denner, collectively the Reporting Persons, filed Amendment No. 5 to their Schedule 13D regarding their beneficial ownership of Innoviva, Inc. common stock.
• As of March 14, 2025, the Reporting Persons beneficially owned 2,966,022 shares, representing approximately 4.73% of Innoviva's outstanding shares.
• This percentage is based on 62,675,545 shares outstanding as of February 14, 2025, as reported by Innoviva in its Form 10-K.
• The reduction in ownership occurred through a series of open market dispositions (sales) of shares by Sarissa Funds.
• On March 10, 2025, 123,476 shares were sold at a weighted average price of $17.5280 per share, totaling $2,164,287.
• On March 11, 2025, 73,999 shares were sold at a weighted average price of $17.6692 per share, totaling $1,307,503.
• On March 12, 2025, 226,800 shares were sold at a weighted average price of $17.5004 per share, totaling $3,969,102.
• On March 13, 2025, 1,846,864 shares were sold at a weighted average price of $17.0605 per share, totaling $31,508,476.
• As of the close of business on March 13, 2025, the Reporting Persons ceased to be beneficial owners of more than five percent of Innoviva's shares and are no longer subject to Rule 13d-1(a) reporting requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative as a major activist investor has significantly reduced its stake and exited its position as a 5%+ beneficial owner, which can be interpreted as a loss of confidence or a strategic exit.

Negatives

• Sarissa Capital Management LP, a notable activist investor, has significantly reduced its stake in Innoviva, Inc. to below the 5% threshold, signaling a potential loss of conviction or strategic exit from its active involvement.
• The disposition of over 2.27 million shares in a short period could exert downward pressure on the stock price or indicate a lack of perceived future upside by a sophisticated investor.

Future Outlook

The document primarily details a past change in beneficial ownership and the cessation of reporting requirements for the Reporting Persons. It does not provide any forward-looking statements or guidance regarding Innoviva, Inc.'s future performance or strategic direction.

Industry Context

This filing reflects a significant reduction in stake by an activist investment firm, Sarissa Capital, in a biotechnology company, Innoviva. While the document itself does not provide broader industry context, such a move by an activist investor can signal a shift in their investment thesis regarding the company or the sector, potentially indicating that their strategic objectives for the company have been met or are no longer pursued.

Stakeholder Impact

• Shareholders: May interpret the reduction in stake by Sarissa Capital as a negative signal, potentially leading to a decline in share price due to reduced investor confidence or the perception of a lack of future catalysts from an activist investor.

Next Steps

• The Reporting Persons are no longer subject to the reporting requirements of Rule 13d-1(a) of the Exchange Act as of March 13, 2025.

Key Dates

Recommendation

Keywords

Innoviva, Sarissa Capital Management, Alexander J. Denner, Schedule 13D, beneficial ownership, stake reduction, common stock, share disposition, activist investor